Lipid-lowering drugs. An overview of indications and optimum therapeutic use. (Q39764449)

14 September 2017

1 reference

title

Lipid-lowering drugs. An overview of indications and optimum therapeutic use. (English)

1 reference

14 September 2017

D R Illingworth

1

1 reference

PubMed ID

3552597

14 September 2017

language of work or name

1 reference

1 March 1987

1 reference

14 September 2017

1 reference

14 September 2017

33

1 reference

14 September 2017

3

1 reference

14 September 2017

259-279

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-198733030-00003

14 September 2017

0 references

cites work

Pathogenesis and management of lipoprotein disorders

1 reference

12 December 2020

Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia

1 reference

12 December 2020

Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man

1 reference

12 December 2020

Type III hyperlipoproteinemia: recent insights into the genetic defect of familial dysbetalipoproteinemia

1 reference

12 December 2020

Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

1 reference

12 December 2020

Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: effects on cholesterol balance

1 reference

12 December 2020

Influence of combined therapy with mevinolin and interruption of bile-acid reabsorption on low density lipoproteins in heterozygous familial hypercholesterolemia

1 reference

12 December 2020

The influence of mevinolin on the adrenal cortical response to corticotropin in heterozygous familial hypercholesterolemia

1 reference

12 December 2020

High-density lipoprotein metabolism

1 reference

12 December 2020

Familial type II hyperlipoproteinemia with coronary heart disease: effect of diet-colestipol-nicotinic acid treatment

1 reference

12 December 2020

Neomycin and plasma lipoproteins in type II hyperlipoproteinemia

1 reference

12 December 2020

Disorders of lipid transport--update 1983.

1 reference

12 December 2020

Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects

1 reference

12 December 2020

Normalization of plasma lipoprotein concentrations in patients with type II hyperlipoproteinemia by combined use of neomycin and niacin.

1 reference

12 December 2020

Influence of nicotinic acid on serum cholesterol in man.

1 reference

12 December 2020

Reduced LDL- and increased HDL-apoproteins in patients with hypercholesterolaemia under treatment with bezafibrate

1 reference

12 December 2020

Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study

1 reference

12 December 2020

Consensus conference. Lowering blood cholesterol to prevent heart disease

1 reference

12 December 2020

WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators

1 reference

12 December 2020

Colestipol plus nicotinic acid in treatment of heterozygous familial hypercholesterolaemia

1 reference

12 December 2020

Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen

1 reference

12 December 2020

Pediatric primary prevention of atherosclerosis

1 reference

12 December 2020

TSH response to TRH in euthyroid, hypercholesterolemic patients treated with graded doses of dextrothyroxine

1 reference

12 December 2020

A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators

1 reference

12 December 2020

Probucol with colestipol in the treatment of hypercholesterolemia

1 reference

12 December 2020

Acute Muscular Syndrome Associated with Administration of Clofibrate

1 reference

12 December 2020

Effects of oxandrolone on plasma triglycerides and postheparin lipolytic activity in patients with types III, IV, and V familial hyperlipoproteinemia

1 reference

12 December 2020

Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin

1 reference

12 December 2020

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

1 reference

12 December 2020

The effect of treatment with clofibrate on hepatic triglyceride and lipoprotein lipase activities of post heparin plasma in male patients with hyperlipoproteinemia

1 reference

12 December 2020

Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia

1 reference

12 December 2020

Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent

1 reference

12 December 2020

Metabolic relationships among the plasma lipoproteins. Reciprocal changes in the concentrations of very low and low density lipoproteins in man.

1 reference

12 December 2020

Treatment of homozygous familial hypercholesterolaemia with probucol.

1 reference

12 December 2020

Hypercholesterolemia persisting after distal ileal bypass: response to mevinolin

1 reference

12 December 2020

Mechanism of action of gemfibrozil on lipoprotein metabolism

1 reference

12 December 2020

Treatment of Hypercholesterolemia with Neomycin — A Time for Reappraisal

1 reference

12 December 2020

Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease. Effects on metabolism of low-density lipoproteins

1 reference

12 December 2020

Clinical Pharmacokinetics of Hypolipidaemic Drugs

1 reference

12 December 2020

Ciprofibrate in the therapy of type II hypercholesterolemia. A double-blind trial

1 reference

12 December 2020

Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism

1 reference

12 December 2020

Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia

1 reference

12 December 2020

Clofibrate and niacin in coronary heart disease

1 reference

12 December 2020

Fenofibrate therapy of hyperlipoproteinaemia a dose—response study and a comparison with clofibrate

1 reference

12 December 2020

Prostacyclin production augmented in the short term by nicotinic acid

1 reference

12 December 2020

Treatment of hypercholesterolemia.

1 reference

12 December 2020

Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridemia

1 reference

12 December 2020

Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia

1 reference

12 December 2020

Influence of Gemfibrozil and Clofibrate on Metabolism of Cholesterol and Plasma Triglycerides in Man

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering

1 reference

12 December 2020

Effect of probucol on the activity of postheparin plasma lipoprotein lipase and hepatic lipase

1 reference

12 December 2020

Effects of probucol on low density lipoprotein removal and high density lipoprotein synthesis

1 reference

12 December 2020

Kinetic bases of the primary hyperlipidaemias: studies of apolipoprotein B turnover in genetically defined subjects

1 reference

12 December 2020

Effects of probucol on plasma cholesterol, high and low density lipoprotein cholesterol, and apolipoproteins A1 and A2 in adults with primary familial hypercholesterolemia

1 reference

12 December 2020

Norethindrone acetate, postheparin lipolytic activity, and plasma triglycerides in familial types I, 3, IV, and V hyperlipoproteinemia. Studies in 26 patients and 5 normal persons

1 reference

12 December 2020

Cholestatic lipoproteins--their pathogenesis and significance

1 reference

12 December 2020

Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes

1 reference

12 December 2020

Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia

1 reference

12 December 2020

Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

12 December 2020

Effects of Neomycin Alone and in Combination with Cholestyramine on Serum Cholesterol and Fecal Steroids in Hypercholesterolemic Subjects

1 reference

12 December 2020

An approach to the management of hyperlipoproteinemia

1 reference

12 December 2020

Treatment of common lipoprotein disorders

1 reference

12 December 2020

Internalization-defective LDL receptors produced by genes with nonsense and frameshift mutations that truncate the cytoplasmic domain

1 reference

12 December 2020

Effect of gemfibrozil on biliary lipid metabolism in normolipemic subjects

1 reference

12 December 2020

The coronary drug project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The coronary drug project research group

1 reference

12 December 2020

10.2165/00003495-198733030-00003

Identifiers

DOI

1 reference

PubMed ID

3552597

Dimensions Publication ID

14 September 2017

0 references

1 reference

PubMed ID

3552597